AlphaCentric Advisors LLC Has $2.19 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

AlphaCentric Advisors LLC raised its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 205,000 shares of the biopharmaceutical company’s stock after purchasing an additional 2,500 shares during the quarter. Amicus Therapeutics makes up approximately 1.6% of AlphaCentric Advisors LLC’s investment portfolio, making the stock its 16th largest holding. AlphaCentric Advisors LLC’s holdings in Amicus Therapeutics were worth $2,189,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of FOLD. Duality Advisers LP lifted its holdings in shares of Amicus Therapeutics by 40.3% in the 1st quarter. Duality Advisers LP now owns 37,555 shares of the biopharmaceutical company’s stock worth $442,000 after purchasing an additional 10,792 shares in the last quarter. SG Americas Securities LLC bought a new position in Amicus Therapeutics during the 1st quarter valued at $291,000. Mesirow Institutional Investment Management Inc. bought a new position in Amicus Therapeutics during the 1st quarter valued at $372,000. Swiss National Bank lifted its stake in Amicus Therapeutics by 2.3% during the 1st quarter. Swiss National Bank now owns 434,300 shares of the biopharmaceutical company’s stock valued at $5,116,000 after acquiring an additional 9,900 shares in the last quarter. Finally, Sei Investments Co. lifted its stake in Amicus Therapeutics by 9.5% during the 1st quarter. Sei Investments Co. now owns 222,715 shares of the biopharmaceutical company’s stock valued at $2,624,000 after acquiring an additional 19,366 shares in the last quarter.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total value of $79,500.00. Following the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $9,398,532.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have sold a total of 22,500 shares of company stock valued at $253,275 in the last quarter. 2.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

FOLD has been the topic of a number of recent analyst reports. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 31st. Morgan Stanley reduced their target price on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 target price on shares of Amicus Therapeutics in a report on Friday, September 20th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, August 16th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $17.13.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $11.33 on Tuesday. The company has a debt-to-equity ratio of 2.93, a current ratio of 2.75 and a quick ratio of 2.26. The stock’s 50-day simple moving average is $11.15 and its two-hundred day simple moving average is $10.59. Amicus Therapeutics, Inc. has a 52-week low of $9.02 and a 52-week high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05). The firm had revenue of $126.67 million for the quarter, compared to analysts’ expectations of $121.21 million. Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The business’s quarterly revenue was up 34.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.15) EPS. As a group, equities analysts forecast that Amicus Therapeutics, Inc. will post -0.06 earnings per share for the current year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.